ClinicalTrials.gg
CompletedNCT03372382IVYUpdated Jul 2, 2019Results posted

Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section

A Phase 4 interventional study of Ibuprofen and Acetaminophen in Opioid Use and Pain, Postoperative, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by The University of Texas Health Science Center, Houston · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston — 1 open to participants now, 1 under way, none of them phase 3. Pain, Postoperative · The University of Texas Health Science Center, Houston.

Enrollment
2nd of 16
170 · median 55
Started
2017
the only one that year
Phase 4
13 of 18
none open now
Registered
6th of 18
by date

Among the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 13 in phase 4, and was the 6th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

1 of the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

Postpartum patients delivered by cesarean section will be randomized to NSAIDS Vs NSAIDS plus opioid

Read the detailed description

Women will be approached priors to discharge from the hospital, if they meet inclusion criteria and consent for the study, they will be randomized to one of two possible analgesic regimens. They will be followed at 1-2 weeks and 4-6 weeks after discharge to assess pain level.

03

Conditions studied

  • Opioid Use
  • Pain, Postoperative

Browse trials for

Keywords

  • postpartum
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English or Spanish speaker women who had a cesarean section

Exclusion criteria

Exclusion Criteria:

  • Inability or refusal to provide .
  • Reported current or prior opioid or benzodiazepine use disorder, including urine drug screen positive for a non prescribed opioid or benzodiazepine upon admission or during prenatal care.
  • Current treatment with methadone, buprenorphine or buprenorphine plus naloxone.
  • Known alcoholism disorder.
  • Severe renal or hepatic impairment.
  • Known creatinine > 1.5 at the time of delivery or severe proteinuria leading to diagnosis of renal disease prior to delivery.
  • Severe peptic ulcer disease
  • Severe asthma (if patient has asthma but has previously tolerated NSAIDS, she will be allowed to participate)
  • Known CYP450/CY92D6 mutation conferring opioid ultra-rapid metabolizer status.
  • Allergy to any of the study drugs (anaphylaxis).
  • Incarcerated or institutionalized patients.
  • Inability to follow up as outpatient in our outpatient clinic.
  • wound dehiscence or infection diagnosed prior to discharge from the hospital
  • wound vac placed prior to discharge from the hospital
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    ibuprofen plus acetaminophen

    women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen

    Drug: Ibuprofen · Drug: Acetaminophen

  • Experimental
    ibuprofen plus acetaminophen/hydrocodone

    women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)

    Drug: Ibuprofen · Drug: Norco

Interventions

06

What researchers measure

Primary outcomes

  1. Pain Level

    pain level measured by objective and subjective scales. 1- Objective scale: visual analogue pain score (VAS). It is a 100 mm line, patients will be instructed to mark a point in the line that represents their pain level. A point towards the left will mean "less pain" and a point towards the right will mean "more pain". After the patient makes a selection, the research team will measure where the selected point is (in cm). minimum measurement =0mm = no pain. maximum measurement=100mm=worst pain.

    Time frame: 2-4 weeks postpartum

Secondary outcomes

  1. Patient Satisfaction

    patient satisfaction as measured by the following scale: 1(very dissatisfied) 2(somewhat dissatisfied) 3(neutral) 4(satisfied) 5(very satisfied)

    Time frame: 2-4 weeks postpartum

07

Results

Posted Jul 2, 2019

Participant flow

recruitment start date: 12/2017 recruitment end date: 03/2018

Participant flow — Overall Study
MilestoneIbuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/Hydrocodone
Started8585
Completed7681
Not completed94

Outcome measures

PrimaryPain Level

pain level measured by objective and subjective scales. 1- Objective scale: visual analogue pain score (VAS). It is a 100 mm line, patients will be instructed to mark a point in the line that represents their pain level. A point towards the left will mean "less pain" and a point towards the right will mean "more pain". After the patient makes a selection, the research team will measure where the selected point is (in cm). minimum measurement =0mm = no pain. maximum measurement=100mm=worst pain.

Time frame:
2-4 weeks postpartum
Reported as:
Mean · millimeters on a scale
Pain Level
millimeters on a scaleIbuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/Hydrocodone
Pain Level12.3 ± 19.515.9 ± 20.4
Statistical analysis
  • Ibuprofen Plus Acetaminophen vs Ibuprofen Plus Acetaminophen/Hydrocodone · Mean difference (final values): 4.8 · 95% CI -2.1 to 11.9The upper boundary of the CI is out of pre-specified limits.
SecondaryPatient Satisfaction

patient satisfaction as measured by the following scale: 1(very dissatisfied) 2(somewhat dissatisfied) 3(neutral) 4(satisfied) 5(very satisfied)

Time frame:
2-4 weeks postpartum
Reported as:
Count of participants · Participants
Patient Satisfaction
ParticipantsIbuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/Hydrocodone
1(very dissatisfied)24
2(somewhat dissatisfied)33
3(neutral)1112
4(satisfied)2316
5(very satisfied)3746

Adverse events

Collected over four months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen Plus Acetaminophen0/85 (0%)0/85 (0%)14/85 (16.5%)
Ibuprofen Plus Acetaminophen/Hydrocodone0/85 (0%)0/85 (0%)25/85 (29.4%)
Most frequent other events
Most frequent other events
EventIbuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/Hydrocodone
constipationGastrointestinal disorders7/8513/85
somnolenceGeneral disorders4/8513/85
nausea / emesisGastrointestinal disorders2/854/85
GERDGastrointestinal disorders1/852/85
itchingGeneral disorders1/852/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/HydrocodoneTotal
Mean28.39 ± 5.828.05 ± 5.6428.2 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/HydrocodoneTotal
Female8585170
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibuprofen Plus AcetaminophenIbuprofen Plus Acetaminophen/HydrocodoneTotal
Race — African american364985
Race — Hispanic342963
Race — white13316
Race — other246
08

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Apr 2018, 3 months.

Results were first posted in Jul 2019, 1 year 2 months after primary completion.

Of 533 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 3 months is below that.

Counting every sponsor, half of 543 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2017
First posted
Dec 13, 2017
StartActual
Dec 13, 2017
Primary completionActual
Apr 10, 2018
CompletionActual
Apr 10, 2018
Results first posted
Jul 2, 2019
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03372382
Responsible party
Jenifer Dinis Ballestas (MD, Maternal Fetal Medicine Fellow, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Dec 13, 2017
Start date
Dec 13, 2017
Primary completion
Apr 10, 2018
Completion
Apr 10, 2018
Results posted
Jul 2, 2019
Last update
Jul 2, 2019

Study contacts

Jenifer Dinis, MD
principal investigator · UT Houston, McGovern Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion